rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AKBA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Akebia Therapeutics Inc (AKBA) (Q3 2026) Earnings Call Highlights: Vafseo Demand Outpaces ...
      Nov 6Yahoo FinanceAKBA
      Akebia Therapeutics Q3 2026 Earnings Call Transcript
      Nov 5BenzingaAKBA
      Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
      Nov 5Yahoo FinanceAKBA
      Akebia Therapeutics: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceAKBA
      Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

      Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025 Q3 2026 Vafseo® (vadadustat) net product revenues of $14.8 million, impacted by customer inventory reduction and market dynamics as Vafseo's TDAPA expiration approaches Positive VOICE data demonstrating statistically significant evidence of improved safety outcomes for patients treated with vadadustat versus an ESA presented by U.S. Renal

      Nov 5Yahoo FinanceAKBA
      Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
      Oct 29Yahoo FinanceAKBA
      Akebia Therapeutics receives Nasdaq notice for minimum bid price deficiency
      Oct 23Investing.comAKBA
      Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
      Oct 7Yahoo FinanceAKBA
      Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026

      Additional poster presentations highlight Vafseo® (vadadustat) clinical and economic dataWALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced upcoming presentations at the American Society of Nephrology Kidney Week 2026 (ASN Kidney Week), which will take place in Denver, CO from October 21-25, 2026. U.S. Renal Care will present the results

      Oct 6Yahoo FinanceAKBA
      Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on September 30, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(

      Oct 1Yahoo FinanceAKBA
      Akebia doses first patient in Phase 2 kidney disease trial
      Sep 14Investing.comAKBA
      Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

      Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the first patient has been dosed in its Phase 2 basket trial evaluating ebribafusp for the treatment of rare complement-mediat

      Sep 14Yahoo FinanceAKBA
      Akebia Therapeutics Doses First Patient in Phase 2 Ebribafusp Trial
      Sep 14Yahoo FinanceAKBA
      Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on August 31, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(

      Sep 1Yahoo FinanceAKBA
      Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston

      CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, which will take place in Boston, September 8 – 10, 2026. During meetings, management will disc

      Sep 1Yahoo FinanceAKBA

      This is the newest page. Registered accounts read further back.